8% on placebo) and with low risk of symptomatic or confirmed hypoglycemia (5.5% vs
Another study found that liraglutide also reduced the activation of microglial cells in the brain's cortex and thalamus in diabetic rats by lowering the expression of NLRP3 protein, a marker of inflammation in brain microglia [104]
It is approved for individuals with a body mass index (BMI) of 30 or higher, or for those with a BMI of 27 or higher who also have at least one weight-related condition such as high blood pressure, high cholesterol, or sleep apnea
Despite suggestions that the gastric emptying effects are greatest in the first 12 weeks and that the effect wanes weeks later, there is no certainty, and the impact on a given patient might be variable
The administration of GLP-1 enhances the feeling of satiety
When drug levels are temporarily higher due to early dosing, gastric emptying slows further